HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yukitaka Ueki Selected Research

Adrenal Cortex Hormones (Corticosteroids)

9/2022Comparison of complications during 1-year follow-up between remitting seronegative symmetrical synovitis with pitting edema syndrome and elderly-onset rheumatoid arthritis.
8/2012High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yukitaka Ueki Research Topics

Disease

61Rheumatoid Arthritis
09/2022 - 04/2002
6Type 2 Diabetes Mellitus (MODY)
03/2010 - 02/2002
5Rheumatic Diseases (Rheumatism)
09/2022 - 01/2016
5Infections
09/2022 - 06/2011
5Neoplasms (Cancer)
06/2014 - 08/2010
4Familial Mediterranean Fever (Periodic Disease)
09/2020 - 04/2016
3Synovitis
09/2022 - 08/2012
3Cardiovascular Diseases (Cardiovascular Disease)
09/2022 - 08/2003
3Stroke (Strokes)
03/2020 - 02/2002
3Adult-Onset Still's Disease
09/2019 - 12/2017
3Osteoporosis
05/2019 - 07/2011
3Insulin Resistance
10/2008 - 02/2002
2Edema (Dropsy)
09/2022 - 08/2012
2Herpes Zoster
05/2021 - 01/2017
2Fever (Fevers)
09/2020 - 08/2012
2Genetic Predisposition to Disease (Genetic Predisposition)
09/2019 - 12/2017
2Connective Tissue Diseases (Connective Tissue Disease)
11/2016 - 01/2015
2Parkinson Disease (Parkinson's Disease)
06/2014 - 06/2014
2Arthritis (Polyarthritis)
08/2012 - 04/2011
2Inflammation (Inflammations)
04/2011 - 08/2003
2Obesity
07/2002 - 02/2002
1Immunoglobulin G4-Related Disease
01/2022
1T-Cell Leukemia (Leukemia, T Cell)
09/2021
1Sarcoidosis (Schaumann Disease)
11/2020
1Vasculitis (Vasculitides)
11/2020
1Cerebral Infarction
03/2020
1Ischemic Stroke
03/2020
1Thromboembolism
03/2020
1Atrial Fibrillation
03/2020
1HTLV-I Infections (HTLV-I Infection)
01/2018
1Alcoholic Fatty Liver
01/2018
1Macrophage Activation Syndrome
12/2017
1Fasciitis (Fascitis)
11/2017
1Myositis (Idiopathic Inflammatory Myopathies)
11/2017
1Diabetes Mellitus
01/2017
1Lung Diseases (Lung Disease)
01/2017
1Takayasu Arteritis (Arteritis, Takayasu's)
12/2016
1Pathologic Processes
11/2016
1Bone Resorption
11/2016
1Bone Fractures (Bone Fracture)
11/2016
1Neutropenia
01/2016

Drug/Important Bio-Agent (IBA)

20tocilizumab (atlizumab)FDA Link
01/2021 - 04/2011
18Biological ProductsIBA
01/2022 - 01/2010
13Methotrexate (Mexate)FDA LinkGeneric
05/2021 - 12/2010
10Antirheumatic Agents (DMARD)IBA
01/2022 - 03/2014
8Etanercept (Enbrel)FDA Link
01/2017 - 01/2009
7Tumor Necrosis Factor InhibitorsIBA
09/2021 - 06/2011
6tofacitinibIBA
01/2022 - 01/2017
6Abatacept (Orencia)FDA Link
07/2021 - 09/2014
6Pharmaceutical PreparationsIBA
05/2019 - 12/2002
5Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2021 - 12/2010
5Biomarkers (Surrogate Marker)IBA
07/2021 - 09/2011
4Infliximab (Remicade)FDA Link
12/2018 - 12/2011
3E-SelectinIBA
03/2010 - 02/2002
2SteroidsIBA
09/2022 - 12/2017
2Adrenal Cortex Hormones (Corticosteroids)IBA
09/2022 - 08/2012
2Janus Kinase InhibitorsIBA
03/2022 - 01/2021
2HLA-DRB1 Chains (HLA DRB1)IBA
09/2019 - 12/2017
2GlucocorticoidsIBA
05/2019 - 11/2016
2CytokinesIBA
01/2018 - 04/2016
2Interleukin-6 (Interleukin 6)IBA
11/2017 - 01/2014
2Anti-Citrullinated Protein AntibodiesIBA
01/2017 - 10/2010
2Adalimumab (Humira)FDA Link
01/2017 - 09/2011
2Prednisolone (Predate)FDA LinkGeneric
01/2017 - 11/2016
2Rheumatoid FactorIBA
08/2012 - 08/2011
2Immunoglobulin M (IgM)IBA
08/2011 - 10/2010
2SelectinsIBA
03/2010 - 02/2002
2C-Reactive ProteinIBA
12/2006 - 08/2003
2Insulin (Novolin)FDA Link
08/2003 - 02/2002
2Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
07/2002 - 02/2002
2Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
07/2002 - 02/2002
1Conjugate VaccinesIBA
03/2022
1Complement System Proteins (Complement)IBA
01/2022
1Immunoglobulin G (IgG)IBA
01/2022
1upadacitinibIBA
05/2021
1baricitinibIBA
01/2021
116S Ribosomal RNAIBA
11/2020
1ametantrone (HAQ)IBA
11/2020
1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
11/2020
1NucleotidesIBA
09/2020
1Tissue Plasminogen Activator (Alteplase)FDA Link
03/2020
1HLA-DQB1 antigen (HLA DQB1)IBA
09/2019
1DenosumabFDA Link
05/2019
1Amyloid (Amyloid Fibrils)IBA
12/2018
1InflammasomesIBA
12/2018
1LipopolysaccharidesIBA
01/2018
1Phosphatidylinositols (Phosphatidylinositol)IBA
01/2018
1Proteins (Proteins, Gene)FDA Link
01/2018
1Transaminases (Aminotransferases)IBA
01/2018
1Interleukin-17 (Interleukin 17)IBA
12/2016
1Diphosphonates (Bisphosphonates)IBA
11/2016
1Vitamin DFDA LinkGeneric
11/2016
1alfacalcidolIBA
11/2016
1Alendronate (Alendronate Sodium)FDA LinkGeneric
11/2016
1Serum AlbuminIBA
01/2016
1Folic Acid (Vitamin M)FDA LinkGeneric
01/2016

Therapy/Procedure

26Therapeutics
09/2022 - 04/2002
2Remission Induction
08/2011 - 01/2009
1Renal Dialysis (Hemodialysis)
03/2020
1Drug Tapering
12/2019